In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

The following is a summary of “Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Patients with rheumatoid arthritis (RA) undergoing standard-of-care treatment frequently have persisting pain.

US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

Dong-A ST's biosimilar product Imuldosa has been approved by the U.S. Food and Drug Administration (FDA), the Korean ...

World Arthritis Day, observed on October 12 each year, plays a crucial role in raising awareness about the millions of people ...